When the average applies to no one: personalized decision making about potential benefits of lung cancer screening.
about
Lung cancer screening: past, present and futureMultimorbidity and evidence generationLung cancer screening with low-dose computed tomography for primary care providersComparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials.Improving selection criteria for lung cancer screening. The potential role of emphysema.Comparing benefits from many possible computed tomography lung cancer screening programs: extrapolating from the National Lung Screening Trial using comparative modeling.Implementation of new clinical programs in the VHA healthcare system: the importance of early collaboration between clinical leadership and research.Evaluation of the lung cancer risks at which to screen ever- and never-smokers: screening rules applied to the PLCO and NLST cohorts.Clinical characteristics and prognosis of incidentally detected lung cancersLung cancer in patients with chronic obstructive pulmonary disease. Development and validation of the COPD Lung Cancer Screening Score.The Lake Wobegon Effect: Why Most Patients Are at Below-Average RiskAn official American Thoracic Society/American College of Chest Physicians policy statement: implementation of low-dose computed tomography lung cancer screening programs in clinical practice.Airflow Limitation and Histology Shift in the National Lung Screening Trial. The NLST-ACRIN Cohort Substudy.Comorbidities, smoking status, and life expectancy among individuals eligible for lung cancer screeningResults of the national lung cancer screening trial: where are we now?Development and Validation of Risk Models to Select Ever-Smokers for CT Lung Cancer Screening.Targeting of low-dose CT screening according to the risk of lung-cancer death.Delivering high-quality and affordable care throughout the cancer care continuum.The National Lung Screening Trial: results stratified by demographics, smoking history, and lung cancer histology.Identifying high risk individuals for targeted lung cancer screening: Independent validation of the PLCOm2012 risk prediction tool.Lung Cancer Screening in Individuals with Chronic Obstructive Pulmonary Disease. Finding the Sweet Spot.Circulating Inflammation Markers, Risk of Lung Cancer, and Utility for Risk Stratification.Measures of outcome in lung cancer screening: maximising the benefits.Searching for red shirts. Emphysema as a lung cancer screening criterion?A meta-analysis: is low-dose computed tomography a superior method for risky lung cancers screening population?Shared decision-making conversations and smoking cessation interventions: critical components of low-dose CT lung cancer screening programs
P2860
Q26829339-70702477-9E05-4D4E-A849-9AB0A0064D91Q27014802-065BCCDE-19F5-45F6-BC38-94AF91882017Q28390878-BEE037B9-67B5-4C15-8D6A-F2B2A7D43659Q33651094-AF9F96BA-8957-4ACF-AFB8-E63E90F6F3C8Q33735712-BC78D793-2C2C-469D-9DFC-9C504609C9A1Q33825806-E3923AE0-476D-484F-979B-0CDFEA849DC7Q34550897-2DD11A6F-40C3-41FF-9B40-C23101659352Q34611247-9FEC4601-9E55-4EBB-8827-316D0229736BQ35061539-9A7B9095-A8C5-41BC-98DF-ADB898052C2DQ35153428-ECBEFF4E-0691-478E-B78B-33B07DFB73FDQ35748486-FD7F4EE5-BE78-4E0C-B0AE-F22F1781C4CEQ36185930-67C1FD47-8403-4885-B67F-9BC29D037482Q36272396-3F1760BC-45D9-47DC-AFA5-C8B6DC0F19A1Q36348807-AEC98291-4F27-4B9F-8880-1364203C6FDFQ36755186-24EE87D9-78FF-4F77-80CE-B9D51C81CDE6Q36984154-D97383BE-FE5B-44B9-B5D2-D1CCB7AEC3B2Q37198867-FB8827BD-21D6-4BC5-BA57-119989510E22Q37278390-66E5133B-8E9A-488E-A694-1E20B6646377Q37605356-31598EF9-3D8C-48FE-80B6-903D37A3323BQ38935397-1E4DF3B3-DAA5-4F9E-A584-2B1B1FFBC086Q40375169-C7BF9444-75B3-42E2-AA27-1365FF76200BQ41536252-CCD89396-0915-47ED-A019-4D27CDC41A05Q42369335-A66DD71E-A0B9-4EF1-B9CC-7377CDC73E2BQ50448070-07523E09-6D14-4111-AD0E-8F1E71CD8F9BQ51691456-F0675BE3-843C-4CBE-B3CA-AB5DADA0FAFAQ57645241-E836B6A9-7DDE-4BD2-9A10-3A0B8E6A1102
P2860
When the average applies to no one: personalized decision making about potential benefits of lung cancer screening.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
When the average applies to no ...... fits of lung cancer screening.
@en
When the average applies to no ...... fits of lung cancer screening.
@nl
type
label
When the average applies to no ...... fits of lung cancer screening.
@en
When the average applies to no ...... fits of lung cancer screening.
@nl
prefLabel
When the average applies to no ...... fits of lung cancer screening.
@en
When the average applies to no ...... fits of lung cancer screening.
@nl
P1476
When the average applies to no ...... fits of lung cancer screening.
@en
P2093
Michael K Gould
Peter B Bach
P304
P356
10.7326/0003-4819-157-8-201210160-00524
P407
P577
2012-10-01T00:00:00Z